Karl‐Heinz Liesenfeld

Population pharmacokinetic analysis of the oral thrombin inhibitor dabigatran etexilate in patients with non‐valvular atrial fibrillation from the RE‐LY trial

Karl‐Heinz Liesenfeld, Thorsten Lehr, C. Dansirikul et al. · Journal of Thrombosis and Haemostasis · 2011 · 302 citations · Full text

Thrombosis, Cardiovascular Disease, Medicine +10

Effects of the direct thrombin inhibitor dabigatran on <i>ex vivo</i> coagulation time in orthopaedic surgery patients: a population model analysis

Karl‐Heinz Liesenfeld, Hans Günter Schäfer, Iñaki F. Trocóniz et al. · British Journal of Clinical Pharmacology · 2006 · 115 citations · Full text

Population Pharmacokinetic Analysis of the New Oral Thrombin Inhibitor Dabigatran Etexilate (BIBR 1048) in Patients Undergoing Primary Elective Total Hip Replacement Surgery

Iñaki F. Trocóniz, Christiane Tillmann, Karl‐Heinz Liesenfeld et al. · The Journal of Clinical Pharmacology · 2007 · 97 citations

Thrombosis, Venous Thrombosis, Pharmacokinetic Modeling +14

Dabigatran Etexilate in Atrial Fibrillation Patients With Severe Renal Impairment: Dose Identification Using Pharmacokinetic Modeling and Simulation

Thorsten Lehr, Sebastian Haertter, Karl‐Heinz Liesenfeld et al. · The Journal of Clinical Pharmacology · 2011 · 96 citations

Pharmacometric Characterization of Dabigatran Hemodialysis

Karl‐Heinz Liesenfeld, Alexander Staab, Sebastian Härtter et al. · Clinical Pharmacokinetics · 2013 · 45 citations · Full text